Pharma Mar SA 2016 SR
The report highlights PharmaMar Group's activities in 2016, focusing on its commitment to oncology and ophthalmology R&D. Key achievements include the filing of a Marketing Authorization Application for Aplidin in Europe and the commencement of Phase III trials for Lurbinectedin. The company maintained its leadership in R&D investment in Spain, spending 32.8% of its revenues on research. Environmental efforts were underscored by ISO 14001 certifications for its main subsidiaries and a focus on sustainable marine bioprospecting. The group also reported on its workforce of 713 employees, emphasizing gender diversity and stable employment.
Company: Pharma Mar SA
Sector: Manufacturing
Country: Spain
Year: 2016
Type: SR
Pages: 80
Back to company
Pharma Mar SA
Corporate Social Responsibility Report
The report highlights PharmaMar Group's activities in 2016, focusing on its commitment to oncology and ophthalmology R&D. Key achievements include the filing of a Marketing Authorization Application for Aplidin in Europe and the commencement of Phase III trials for Lurbinectedin. The company maintained its leadership in R&D investment in Spain, spending 32.8% of its revenues on research. Environmental efforts were underscored by ISO 14001 certifications for its main subsidiaries and a focus on sustainable marine bioprospecting. The group also reported on its workforce of 713 employees, emphasizing gender diversity and stable employment.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Women on Board
Women in Management
Employees